References
- GotfriedMHKerwinEMLawrenceDLassenCKramerBEfficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studiesCOPD2012962963623020650
- KerwinEMGotfriedMHLawrenceDLassenCKramerBEfficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studiesClin Ther2011331974198422177371
- CazzolaMMacNeeWMartinezFJOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J20083141646918238951
- JonesPMiravitllesMvan derMTKulichKBeyond FEV(1) in COPD: a review of patient-reported outcomes and their measurementInt J Chron Obstruct Pulmon Dis2012769770923093901
- JonesPWPriceDvan der MolenTRole of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2011628929621697993
- JonesPWQuirkFHBaveystockCMLittlejohnsPA self-complete measure of health status for chronic airflow limitation. The St George’s Respiratory QuestionnaireAm Rev Respir Dis1992145132113271595997
- JonesPWHardingGBerryPWiklundIChenWHKlineLNDevelopment and first validation of the COPD Assessment TestEur Respir J20093464865419720809
- MahlerDAWeinbergDHWellsCKFeinsteinARThe measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexesChest1984857517586723384
- BestallJCPaulEAGarrodRGarnhamRJonesPWWedzichaJAUsefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary diseaseThorax19995458158610377201
- TashkinDPCelliBDecramerMBronchodilator responsiveness in patients with COPDEur Respir J20083174275018256071
- LindbergASzalaiZPulleritsTRadeczkyEFast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstructionRespirology20071273273917875063
- O’ConnorRDPatrickDLParasuramanBMartinPGoldmanMComparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthmaJ Asthma20104721722320170333
- Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for Diagnosis, Management, and Prevention of COPD2009 Available at: http://www.goldcopd.org/Accessed August 6, 2014
- JuliousSASample sizes for clinical trials with normal dataStat Med2004231921198615195324
- WechslerMEKelleyJMBoydIOActive albuterol or placebo, sham acupuncture, or no intervention in asthmaN Engl J Med201136511912621751905
- HrobjartssonAGotzschePCIs the placebo powerless? An analysis of clinical trials comparing placebo with no treatmentN Engl J Med20013441594160211372012
- WiseRABartlettSJBrownEDRandomized trial of the effect of drug presentation on asthma outcomes: the American Lung Association Asthma Clinical Research CentersJ Allergy Clin Immunol200912443643819632710
- JonesPWInterpreting thresholds for a clinically significant change in health status in asthma and COPDEur Respir J20021939840411936514
- BrouillardCPepinVMilotJLacasseYMaltaisFEndurance shuttle walking test: responsiveness to salmeterol in COPDEur Respir J20083157958418057052
- GroveALipworthBJReidPEffects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways diseaseThorax1996516896938882074
- OkudanNGokMGokbelHSuerdemMSingle dose of tiotropium improves the 6-minute walk distance in chronic obstructive pulmonary diseaseLung200618420120417006746